Addiction biology research on miRNAs, and their role in the pathophysiology of addiction is enabling gene therapy opportunities
This article lists known miRNAs that may be used one day to diagnose and treat addiction. Besides miRNAs associated with a particular abuse drug, miR132/212, miR124 and miR9 all have a distinct expression profile in various abuse drugs. Based on our research, these miRNAs appear to be pleiotropic, meaning they are regulated in their environment by several different variables or chemicals. Substance consumption, drug type, and the paradigm (i.e., acute vs. chronic) under which they are consumed all affect the addiction manifestation. MiRNA levels appear to change for acute and chronic use, indicating that miRNA isoforms involved in numerous abuse drugs and brain areas (e.g. let7, miR212/132) may function as regulatory hubs for addictive behavior. MiRNA strands compete with each other, work hierarchically, and some miRNA targets have stronger binding affinities than others. Future addiction biology research should focus on miRNAs, and how miRNA expression changes over time. Research investigating how miRNA's expression differs in drug intoxication and recovery should take precedence. Another topic for future research is using polydrugs. Drug studies that analyze many substances together are well known. This is of particular importance, as the presence of several abused drugs increases the likelihood of upregulating or downregulating miRNAs. If miRNAs are linked to nicotine, alcohol, marijuana and opiates, understanding their role in polydrug use is vital. We created a map to highlight miRNAs influenced by drug use in the context of synaptic plasticity pathway genes. These miRNAs and their pathways may open the door to new addictive behavior therapies.Currently, preclinical investigations using miRNAs as biomarkers or disorder therapies, but no clinical trials and only a few preclinical trials are being undertaken. Biomarkers would make it one of today's most researched areas. Research shows promise for miRNAs in rehabilitation despite several roadblocks. MiRNAs can have many downstream effects, making them challenging to use. Indeed, interesting research on circRNAs has shown that they function as a miRNA sponge, possibly limiting the effects of a particular miRNA increase. Like miRNAs, CircRNAs can produce unforeseen results. Because miRNAs' functions vary widely, absorbing miRNAs via circRNAs may hinder therapeutic development. Because of nucleases and phospholipid bilayers, distribution of miRNA to humans was challenging. Passing the delivery barriers using organic and inorganic nanoparticles like peptides, gold, mesoporous silicon, graphene oxide, and iron oxide is a popular technique. MiRNA-based lipid nanoparticles delivery vectors were found to be successful. In our future studies, the main EVs are naturally occurring, biolabeled, and targeted with little toxicity and antigenicity. EVs can pass the essential blood-brain barrier to help cure drug addiction.